The use of paramagnetic particles (PMP) and their detection in a magnetic assay reader (MAR) represent a new """"""""platform"""""""" technology that is adaptable to lateral flow membrane systems. In preliminary studies, the new technology is capable of delivering 3 to 4 logs increased sensitivity over existing lateral flow technologies that use immunogold or enzyme-tagged antibodies. We propose to develop a new rapid lateral flow system for Clostridium difficile toxins A and B using this technology. C. difficile is an excellent candidate to evaluate the technology. This anaerobic pathogen is the leading cause of nosocomial diarrhea and colitis in industrialized countries. Although the current antibody-based tests for C. difficile are more rapid than the tissue culture assay, which is considered the gold standard, they do not offer the same level of sensitivity. In Phase I, we will optimize the conditions needed to develop a PMP test for the toxins of C. difficile. We will optimize the PMP conjugation process, test formatting with separation membrane and capture line processes, evaluate stability, and develop a fecal sample diluent. A prototype device will be developed and we will initiate studies to evaluate performance characteristics. In addition, we will develop antibodies for the detection of iota toxin, a newly recognized C. difficile toxin. Phase II will be a natural extension of Phase I. The technology for producing the device will be transferred to a GMP facility, and we will evaluate GMP produced devices through in-house and on-site studies. Data will be collected and compiled, and 510(k) documents will be prepared. Using the PMP lateral flow technology platform that we will evaluate in Phase I, we will also develop a diagnostic C. difficile panel test, which will be useful for epidemiological and surveillance studies of C. difficile disease. In addition, we will develop a clinical diagnostic panel test for antibiotic associated diarrhea (AAD), including a PMP-based test for C. perfringens enterotoxin, another cause of AAD. The technology developed in this project will be widely applicable for the development of new highly sensitive stool antigen tests.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43AI056523-02
Application #
6783347
Study Section
Special Emphasis Panel (ZRG1-SSS-K (10))
Program Officer
Hall, Robert H
Project Start
2003-08-01
Project End
2006-12-31
Budget Start
2004-08-01
Budget End
2006-12-31
Support Year
2
Fiscal Year
2004
Total Cost
$240,635
Indirect Cost
Name
Techlab, Inc.
Department
Type
DUNS #
614218634
City
Blacksburg
State
VA
Country
United States
Zip Code
24060
Zheng, Limin; Citron, Diane M; Genheimer, Christopher W et al. (2007) Molecular characterization and antimicrobial susceptibilities of extra-intestinal Clostridium difficile isolates. Anaerobe 13:114-20